Avastin +/- Erlotinib Consolidation Chemotherapy After Carboplatin, Paclitaxel, and Avastin (CTA) Induction Therapy for Advanced Ovarian, Fallopian Tube, Primary Peritoneal Cancer & Papillary Serous or Clear Cell Mullerian Tumors
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT00520013 |
|
Recruitment Status :
Completed
First Posted : August 23, 2007
Results First Posted : July 3, 2015
Last Update Posted : July 27, 2018
|
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Ovarian Cancer Fallopian Tube Cancer Primary Peritoneal Cancer Papillary Serous Mullerian Tumor Clear Cell Mullerian Tumor | Drug: bevacizumab Drug: erlotinib Drug: paclitaxel Drug: carboplatin | Phase 2 |
Objectives:
Primary To examine the progression free survival (PFS) of Avastin and Erlotinib (AE) or Avastin (A) as consolidation therapy.
Secondary To examine the toxicity between the two consolidative regimens AE vs. A. To assess the response rate of CTA.
STATISTICAL DESIGN This study uses a randomized selection design. Both consolidation treatment arms are deemed experimental and are compared against a historical control [McGuire WP et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. NEJM 1996: 334:1-6. PMID:7494563]. With 30 patients in a given arm and 6 months of follow-up, there was 80% power to detect a 61.5% increase in median PFS from 13 months to 21 months assuming 1-sided 10% significance.
| Study Type : | Interventional (Clinical Trial) |
| Actual Enrollment : | 60 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | None (Open Label) |
| Primary Purpose: | Treatment |
| Official Title: | A Randomized Phase II Trial of Avastin (A) or Avastin and Erlotinib (AE) as First Line Consolidation Chemotherapy After Carboplatin, Paclitaxel, and Avastin (CTA) Induction Therapy for Newly Diagnosed Advanced Ovarian, Fallopian Tube, Primary Peritoneal Cancer & Papillary Serous or Clear Cell Mullerian Tumors |
| Study Start Date : | August 2007 |
| Actual Primary Completion Date : | October 2010 |
| Actual Study Completion Date : | November 2013 |
| Arm | Intervention/treatment |
|---|---|
|
Experimental: carboplatin/paclitaxel/bevacizumab then bevacizumab
Induction (CTA): Patients received carboplatin IV AUC 5, paclitaxel IV 175 mg/m2 and bevacizumab IV 15 mg/kg on day 1 (+/- 3d) of a 21 day cycle for 6 cycles. Bevacizumab started with cycle 2. Patients with disease progression based on radiographic evaluation after induction could not advance to the randomized consolidation phase. Consolidation (A): Patients received bevacizumab IV 15 mg/kg on day 1 (+/- 3d) of a 21 day cycle for 1 year. |
Drug: bevacizumab
Other Names:
Drug: paclitaxel Other Name: Taxol Drug: carboplatin Other Name: Paraplatin |
|
Experimental: carboplatin/paclitaxel/bevacizumab then bevacizumab/erlotinib
Induction (CTA): Patients received carboplatin IV AUC 5, paclitaxel IV 175 mg/m2 and bevacizumab IV 15 mg/kg on day 1 (+/- 3d) of a 21 day cycle for 6 cycles. Bevacizumab started with cycle 2. Patients with disease progression based on radiographic evaluation after induction could not advance to the randomized consolidation phase. Consolidation (AE): Patients received bevacizumab IV 15 mg/kg on day 1 (+/- 3d) of a 21 day cycle and oral erlotinib 150mg daily for 1 year. |
Drug: bevacizumab
Other Names:
Drug: erlotinib Other Name: Tarceeva Drug: paclitaxel Other Name: Taxol Drug: carboplatin Other Name: Paraplatin |
|
Experimental: carboplatin/paclitaxel/bevacizumab
Induction (CTA): Patients received carboplatin IV AUC 5, paclitaxel IV 175 mg/m2 and bevacizumab IV 15 mg/kg on day 1 (+/- 3d) of a 21 day cycle for 6 cycles. Bevacizumab started with cycle 2. Patients with disease progression based on radiographic evaluation after induction could not advance to the randomized consolidation phase. Consolidation: None |
Drug: bevacizumab
Other Names:
Drug: paclitaxel Other Name: Taxol Drug: carboplatin Other Name: Paraplatin |
- Consolidation Progression-Free Survival [ Time Frame: Assessments occurred every cycle (serologic) and every 3 cycles (radiologic) on consolidation treatment. Pts were allowed on consolidation therapy for up to 1 year and upon treatment discontinuation were followed for another year. ]Consolidation PFS based on the Kaplan-Meier method was defined as the time from the first day of consolidation therapy to documented disease progression (PD) or disease-specific death. Based on RECIST 1.1, radiographic PD was defined as at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum since beginning consolidation, the appearence of one or more new lesions and/or unequivocal progression of existing non-target lesions. Based on Rustin criteria, serlogic PD was a rise in CA125 since beginning of consolidation or previously normal CA125 that rises to >/= 2xULN with either event documented on 2 occasions. Patients who were event-free were censored at the date of their last disease evaluation.
- Consolidation Treatment-related Toxicity Rate [ Time Frame: Assessed every cycle during consolidation treatment and up to 30 days post-treatment. Per protocol, consolidation treatment was a fixed duration of 1 year. ]Consolidation treatment-related toxicity rates based on CTCAEv3 were defined as rates of maximum grade 3 or higher toxicity events with attribution possible, probable or definite occurring during consolidation treatment and up to 30 days post-treatment.
- Consolidation Objective Response Rate [ Time Frame: Assessments occurred every cycle (serologic) and every 3 cycles (radiologic) on consolidation treatment. Pts were allowed on consolidation therapy for up to 1 year. ]Consolidation objective response (OR) was based on RECIST 1.0 criteria with OR defined as achieving partial response (PR) or complete response (CR). Per RECIST 1.0 for target lesions, CR is complete disappearance of all target lesions and PR is at least a 30% decrease in the sum of longest diameter (LD) of target lesions, taking as reference baseline sum LD. For CR or PR, changes in tumor measurements must be confirmed by repeat assessments performed no fewer than 4 weeks after the response criteria are first met. PR or better overall response assumes at a minimum incomplete response/stable disease (SD) for the evaluation of non-target lesions and absence of new lesions. If CA125 disease then OR based on Rustin criteria is a 50% decrease in serum CA125 level from two initially elevated samples confirmed by a 4th sample.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
| Sexes Eligible for Study: | Female |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- 18 years of age and older
- Histological diagnosis of epithelial ovarian carcinoma, fallopian tube cancer, primary peritoneal carcinoma, or papillary serous mullerian carcinoma
- Previous attempted surgical debulking
- Stage III or IV
- Willing and able to undergo second look laparoscopy
- Performance status 0-1 by ECOG scale
- Peripheral neuropathy < grade 2
- Life expectancy of 6 months or greater
Exclusion Criteria:
- Patients with clinically significant cardiovascular disease as outlined in the protocol
- Neutrophil count < 1,500/mm3; platelet count <100,000/m3
- Alkaline phosphatase or bilirubin > 1.5 x ULN, SGOT > 5 x ULN
- Calculated creatinine clearance < 50ml/min
- Prior chemotherapy or radiotherapy for other malignancy except for the treatment for localized breast cancer greater than five years prior to diagnosis
- No more than one cycle of first line chemotherapy with carboplatin and paclitaxel
- Inadequate surgical cytoreduction such that interval cytoreductive surgery could materially improve prognosis
- Concurrent invasive malignancy
- Evidence of bleeding diathesis or coagulopathy
- Evidence of tumor involving major blood vessels on any prior CT scans
- Surgical wound that has failed to close
- Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to Day 0, or anticipation of need for major surgical procedure during the course of this study
- Core biopsy or other minor surgical procedure, excluding placement of a vascular access device, within 7 days prior to study enrollment
- History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within 6 months prior to day 0
- Serious non-healing wound, ulcer, or bone fracture
- Prior treatment with an anti-angiogenic agent
- Any active bleeding
- Active psychiatric disease or neurologic symptoms requiring treatment
- Presence of central nervous system brain metastases
- Proteinuria at screening as demonstrated by criteria in protocol
- Dementia or significantly altered mental status that would prohibit the understanding and/or giving of informed consent
- Known hypersensitivity to Cremophor EL or any component of Avastin
- Active bacterial, viral, or fungal infections
- Receiving any other investigational agent
- History of gastrointestinal perforation
- Prior therapies targeting the epidermal growth factor receptor
- Symptoms of bowel obstruction
- Dependence on TPN or IV hydration
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00520013
| United States, Massachusetts | |
| Massachusetts General Hospital | |
| Boston, Massachusetts, United States, 02114 | |
| Beth Israel Deaconess Medical Center | |
| Boston, Massachusetts, United States, 02115 | |
| Dana-Farber Cancer Institute | |
| Boston, Massachusetts, United States, 02115 | |
| Principal Investigator: | Susana Campos, MD, MPH | Dana-Farber Cancer Institute |
| Responsible Party: | Susana M. Campos, MD, Medical Oncologist., Dana-Farber Cancer Institute |
| ClinicalTrials.gov Identifier: | NCT00520013 |
| Other Study ID Numbers: |
07-039 |
| First Posted: | August 23, 2007 Key Record Dates |
| Results First Posted: | July 3, 2015 |
| Last Update Posted: | July 27, 2018 |
| Last Verified: | July 2018 |
|
Neoplasms Fallopian Tube Neoplasms Peritoneal Neoplasms Mixed Tumor, Mullerian Neoplasms by Site Adnexal Diseases Genital Diseases, Female Female Urogenital Diseases Female Urogenital Diseases and Pregnancy Complications Urogenital Diseases Genital Neoplasms, Female Urogenital Neoplasms Genital Diseases Fallopian Tube Diseases Abdominal Neoplasms |
Digestive System Neoplasms Digestive System Diseases Peritoneal Diseases Neoplasms, Complex and Mixed Neoplasms by Histologic Type Paclitaxel Bevacizumab Carboplatin Erlotinib Hydrochloride Antineoplastic Agents, Phytogenic Antineoplastic Agents Tubulin Modulators Antimitotic Agents Mitosis Modulators Molecular Mechanisms of Pharmacological Action |